Arthur Tzianabos

Dr. Arthur O.
Tzianabos is a Venture Partner at 5AM Venture Management LLC, an Executive Chairman at Stoke Therapeutics, Inc., a Member-Development Board at University of New Hampshire and a President & Chief Executive Officer at Lifordi Immunotherapeutics, Inc. He is on the Board of Directors at Alliance for Regenerative Medicine, Q32 Bio, Inc. and Oxford Biomedica Solutions LLC.
Dr. Tzianabos was previously employed as a Chairman by Akouos, Inc., a Chairman by Homology Medicines, Inc., a President & Chief Scientific Officer by OvaScience, Inc., a Senior VP, Head-Research & Early Development by Shire Plc, an Associate Professor & Member by Harvard Medical School, and a Senior VP, Head-Research & Early Development by Shire Pharmaceuticals, Inc. He also served on the board at DNIB Unwind, Inc. and ArmaGen, Inc. He received his undergraduate degree from Boston College and a doctorate degree from the University of New Hampshire.